{"id":563441,"date":"2021-09-15T13:24:30","date_gmt":"2021-09-15T13:24:30","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=563441"},"modified":"2021-09-15T13:24:30","modified_gmt":"2021-09-15T13:24:30","slug":"primary-hyperoxaluria-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-hyperoxaluria-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_563441.html","title":{"rendered":"Primary Hyperoxaluria Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631697385.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Primary Hyperoxaluria Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631697385.png\" alt=\"Primary Hyperoxaluria Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cPrimary Hyperoxaluria \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Primary Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong>&ldquo;Primary Hyperoxaluria Pipeline Insight&rdquo;<\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Primary Hyperoxaluria pipeline landscapes.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report comprises <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Primary Hyperoxaluria pipeline <\/a><\/strong>drug profiles, including clinical and non-clinical stage products. It also includes the Primary Hyperoxaluria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Primary Hyperoxaluria pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/255701a3069769fd1ae884708e79faf9.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Biocodex, OxThera, Dicerna Pharmaceuticals, etc., are developing therapies for the treatment of Primary Hyperoxaluria.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies such as Stiripentol, Oxabact OC5 &#8211; Oxalobacter formigenes HC-1, DCR-PHXC, are expected to have a significant impact on the&nbsp; Primary Hyperoxaluria market in the coming years.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Primary Hyperoxaluria Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys. There are three known genetic types of PH, each resulting from a mutation in one of three different genes. These genetic mutations cause enzyme deficiencies that manifest in the overproduction of a substrate called oxalate. Abnormal production and accumulation of oxalate lead to recurrent kidney stones, nephrocalcinosis, and chronic kidney disease that may progress to an end-stage renal disease requiring regular dialysis and a dual liver-kidney transplant.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Primary Hyperoxaluria Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stiripentol by Biocodex<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oxabact OC5 &#8211; Oxalobacter formigenes HC-1 by OxThera<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DCR-PHXC by Dicerna Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Primary Hyperoxaluria Pipeline Drug Insight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major Players: Biocodex, OxThera, Dicerna Pharmaceuticals, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline Therapies: Stiripentol, Oxabact OC5 &#8211; Oxalobacter formigenes HC-1, DCR-PHXC, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Late Stage Products (Phase II\/III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Preclinical Stage Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Therapeutics Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>14<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>15<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>17<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>18<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Primary Hyperoxaluria Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>19<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>20<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> @ Primary Hyperoxaluria Drugs Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-hyperoxaluria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Primary Hyperoxaluria Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;Primary Hyperoxaluria-Market Insights, Epidemiology, and Market Forecast&mdash;2030&rsquo; report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Primary Hyperoxaluria Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &lsquo;Primary Hyperoxaluria Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=primary-hyperoxaluria-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=primary-hyperoxaluria-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cPrimary Hyperoxaluria \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Primary Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/primary-hyperoxaluria-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_563441.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-563441","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=563441"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=563441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=563441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=563441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}